Join Fund Library now and get free access to personalized features to help you manage your investments.
U.S. Equity
Click for more information on Fundata’s FundGrade
Click for more information on Fundata’s FundGrade.
Click for more information on Fundata’s ESG Grade
Click for more information on Fundata’s ESG Grade.
2023, 2022, 2021, 2020, 2015
Click for more information on Fundata’s FundGrade
|
NAVPS (05-17-2024) |
$46.82 |
|---|---|
| Change |
-$0.07
(-0.14%)
|
As at April 30, 2024
As at March 31, 2024
As at February 29, 2024
Loading...
Inception Return (July 31, 1995): 7.79%
| Row Heading | Return | Annualized Return | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 Mth | 3 Mth | 6 Mth | YTD | 1 Yr | 2 Yr | 3 Yr | 4 Yr | 5 Yr | 6 Yr | 7 Yr | 8 Yr | 9 Yr | 10 Yr | |
| Fund | -3.18% | 5.35% | 21.83% | 11.33% | 32.47% | 20.33% | 12.22% | 15.58% | 15.80% | 16.54% | 15.70% | 17.90% | 15.13% | 16.64% |
| Benchmark | -2.70% | 7.00% | 19.89% | 10.21% | 24.18% | 16.33% | 12.19% | 16.16% | 13.73% | 14.54% | 13.35% | 15.12% | 13.99% | 14.98% |
| Category Average | -3.34% | 18.94% | 18.94% | 8.14% | 20.65% | 12.22% | 7.69% | 13.48% | 10.38% | 10.73% | 10.14% | 11.37% | 10.04% | 10.81% |
| Category Rank | 680 / 1,370 | 784 / 1,364 | 391 / 1,349 | 339 / 1,355 | 179 / 1,285 | 48 / 1,226 | 112 / 1,153 | 276 / 1,090 | 35 / 989 | 34 / 887 | 62 / 815 | 27 / 716 | 34 / 650 | 25 / 575 |
| Quartile Ranking | 2 | 3 | 2 | 2 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 |
| Return % | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Jan | Feb | Mar | Apr |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Fund | 6.06% | 2.54% | 2.57% | 1.76% | -5.03% | 0.86% | 8.09% | 1.25% | 5.68% | 6.85% | 1.83% | -3.18% |
| Benchmark | 0.62% | 3.76% | 2.72% | 1.05% | -4.85% | 0.44% | 6.86% | 1.80% | 3.00% | 6.70% | 3.07% | -2.70% |
37.88% (February 2000)
-21.85% (February 2001)
| Return % | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|---|---|---|
| Fund | 26.86% | 21.81% | -0.84% | 22.08% | 8.77% | 25.94% | 29.23% | 24.97% | -22.89% | 37.42% |
| Benchmark | 24.19% | 20.77% | 8.65% | 13.80% | 3.98% | 25.18% | 16.07% | 28.16% | -12.52% | 23.32% |
| Category Average | 16.59% | 10.40% | 6.16% | 13.43% | -2.19% | 22.72% | 13.97% | 23.22% | -14.41% | 18.85% |
| Quartile Ranking | 1 | 1 | 4 | 1 | 1 | 2 | 1 | 2 | 4 | 1 |
| Category Rank | 26/ 548 | 85/ 639 | 595/ 687 | 110/ 777 | 89/ 869 | 304/ 944 | 138/ 1,057 | 454/ 1,133 | 949/ 1,190 | 117/ 1,254 |
37.42% (2023)
-22.89% (2022)
| Name | Percent |
|---|---|
| US Equity | 92.72 |
| Cash and Equivalents | 3.51 |
| International Equity | 3.38 |
| Canadian Equity | 0.40 |
| Other | -0.01 |
| Name | Percent |
|---|---|
| Technology | 66.12 |
| Healthcare | 20.87 |
| Cash and Cash Equivalent | 3.51 |
| Financial Services | 2.60 |
| Consumer Services | 2.31 |
| Other | 4.59 |
| Name | Percent |
|---|---|
| North America | 96.63 |
| Europe | 2.94 |
| Latin America | 0.30 |
| Asia | 0.14 |
| Other | -0.01 |
| Name | Percent |
|---|---|
| Microsoft Corp | 10.25 |
| NVIDIA Corp | 9.40 |
| Alphabet Inc Cl A | 7.63 |
| Apple Inc | 7.08 |
| Meta Platforms Inc Cl A | 5.29 |
| Eli Lilly and Co | 3.03 |
| Broadcom Inc | 2.42 |
| UnitedHealth Group Inc | 2.13 |
| Merck & Co Inc | 1.91 |
| Salesforce Inc | 1.70 |
RBC Life Science and Technology Fund Series A
Median
Other - U.S. Equity
| Standard Deviation | 16.92% | 15.82% | 15.17% |
|---|---|---|---|
| Beta | 1.09% | 1.02% | 1.10% |
| Alpha | -0.01% | 0.02% | 0.00% |
| Rsquared | 0.87% | 0.87% | 0.85% |
| Sharpe | 0.60% | 0.88% | 1.00% |
| Sortino | 0.90% | 1.34% | 1.47% |
| Treynor | 0.09% | 0.14% | 0.14% |
| Tax Efficiency | 100.00% | 100.00% | 100.00% |
| Volatility |
|
|
|
| Key Ratio | 1 Yr | 3 Yr | 5 Yr | 10 Yr |
|---|---|---|---|---|
| Standard Deviation | 13.50% | 16.92% | 15.82% | 15.17% |
| Beta | 1.01% | 1.09% | 1.02% | 1.10% |
| Alpha | 0.07% | -0.01% | 0.02% | 0.00% |
| Rsquared | 0.77% | 0.87% | 0.87% | 0.85% |
| Sharpe | 1.81% | 0.60% | 0.88% | 1.00% |
| Sortino | 4.17% | 0.90% | 1.34% | 1.47% |
| Treynor | 0.24% | 0.09% | 0.14% | 0.14% |
| Tax Efficiency | 100.00% | 100.00% | 100.00% | 100.00% |
The E, S, and G scores are averaged for each security in the portfolio, to arrive at an ESG score for each security. We take the portfolio weighted average of the ESG scores for each fund and rank them against their peers to arrive at the Fundata ESG Score from 0-100.
Three scores under the Environment bucket are averaged to yield the Fundata Environment Score for each fund from 0-100: (1) Pollution Prevention, (2) Environmental Transparency, (3) Resource Efficiency.
Six scores under the Social bucket are averaged to yield the Fundata Social Score for each fund from 0-100. (1) Compensation and Satisfaction, (2) Diversity and Rights, (3) Education and Work Conditions, (4) Community and Charity, (5) Human Rights, (6) Sustainability Integration.
Three scores under the governance bucket are averaged to yield the Fundata Governance Score for each fund from 0-100: (1) Board Effectiveness, (2) Management Ethics, (3) Disclosure and Accountability.
Powered by OWL Analytics. For more information, please contact Fundata Canada.
| Start Date | July 31, 1995 |
|---|---|
| Instrument Type | Mutual Fund |
| Share Class | Commission Based Advice |
| Legal Status | Trust |
| Sales Status | Open |
| Currency | CAD |
| Distribution Frequency | Annual |
| Assets ($mil) | $1,741 |
| FundServ Code | Load Code | Sales Status |
|---|---|---|
| RBF274 |
The objective of the fund is to provide long-term capital growth. The fund invests primarily in equity securities of U.S. companies whose businesses relate to life sciences and technology and are expected to benefit from scientific and technological advances.
The fund’s investment process is primarily based on fundamental research, although the portfolio manager will also consider quantitative and technical factors. Stock selection decisions are ultimately based on an understanding of the company, its business and its outlook. Life science investments include biotechnology, medical devices and services, pharmaceuticals and medical instruments.
| Name | Start Date |
|---|---|
| Rob Cavallo | 01-01-2014 |
| Marcello Montanari | 02-22-2021 |
| Fund Manager | RBC Global Asset Management Inc. |
|---|---|
| Advisor | RBC Global Asset Management Inc. |
| Custodian | RBC Investor Services Trust (Canada) |
| Registrar | RBC Global Asset Management Inc. |
| Distributor | Royal Mutual Funds Inc. |
| Auditor | PriceWaterhouseCoopers LLP |
| RSP Eligible | Yes |
|---|---|
| PAC Allowed | Yes |
| PAC Initial Investment | 25 |
| PAC Subsequent | 25 |
| SWP Allowed | Yes |
| SWP Min Balance | 10,000 |
| SWP Min Withdrawal | 100 |
| MER | 2.05% |
|---|---|
| Management Fee | 1.75% |
| Load | No Load |
| FE Max | - |
| DSC Max | - |
| Trailer Fee Max (FE) | - |
| Trailer Fee Max (DSC) | - |
| Trailer Fee Max (NL) | 1.00% |
| Trailer Fee Max (LL) | - |
Join Fund Library now and get free access to personalized features to help you manage your investments.
Fund Library
